Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ayaka Kaku"'
Autor:
Masanao Kyuuma, Ayaka Kaku, Chiemi Mishima-Tsumagari, Bunichiro Ogawa, Mayumi Endo, Yunoshin Tamura, Kei-ichiro Ishikura, Masashi Mima, Yutaka Nakanishi, Yasuyuki Fujii
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Biologics have become an important component of treatment strategies for a variety of diseases, but the immunogenicity of large immune complexes (ICs) and aggregates of biologics may increase risk of adverse events is a concern for biologics and it r
Externí odkaz:
https://doaj.org/article/93e7dbb80a1a452d968da965f61623be
Autor:
Hirohiko Hikichi, Tetsuaki Hiyoshi, Toshiyuki Marumo, Yasumitsu Tomishima, Ayaka Kaku, Izumi Iida, Hiroki Urabe, Tomoko Tamita, Akito Yasuhara, Jun-ichi Karasawa, Shigeyuki Chaki
Publikováno v:
Journal of Pharmacological Sciences, Vol 127, Iss 3, Pp 352-361 (2015)
Glutamatergic dysfunction has been implicated in psychiatric disorders such as schizophrenia. The stimulation of metabotropic glutamate (mGlu) 2 receptor has been shown to be effective in a number of animal models of schizophrenia. In this study, we
Externí odkaz:
https://doaj.org/article/b56722cac0fc4fd59c23db537c537189
Publikováno v:
Journal of Pharmacological Sciences, Vol 122, Iss 1, Pp 10-16 (2013)
Abstract.: Glutamatergic dysfunction has been implicated in psychiatric disorders such as schizophrenia. Both the stimulation of the metabotropic glutamate (mGlu) 2/3 receptor and the blockade of the mGlu1 receptor have been shown to be effective in
Externí odkaz:
https://doaj.org/article/64f65c83271e477c8d44d5feecae42fb
Autor:
Ayaka Kaku-Fukumoto, Noriko Hino, Hirohiko Hikichi, Dai Nozawa, Jun-ichi Karasawa, Toshio Nakamura, Emi Tatsuda, Shigeyuki Chaki, Yasumitsu Tomishima, Toshiyuki Marumo, Toshiharu Shimazaki, Makiko Kotani, Hiroko Komiyama
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 375:276-285
Histamine H3 receptor antagonists/inverse agonists are known to enhance the activity of histaminergic neurons in the brain, thereby promoting arousal and cognition. Here, we report the in vitro and in vivo pharmacological profiles for a newly synthes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cf1b46a58c5f29e719fa092f8a420ec
https://doi.org/10.1124/jpet.120.000185
https://doi.org/10.1124/jpet.120.000185
Autor:
Noriko, Hino, Toshiyuki, Marumo, Makiko, Kotani, Toshiharu, Shimazaki, Ayaka, Kaku-Fukumoto, Hirohiko, Hikichi, Jun-Ichi, Karasawa, Yasumitsu, Tomishima, Hiroko, Komiyama, Emi, Tatsuda, Dai, Nozawa, Toshio, Nakamura, Shigeyuki, Chaki
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 375(2)
Histamine H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d4bb83aca81af8a17a5879f4ee7f1340
https://pubmed.ncbi.nlm.nih.gov/32862143
https://pubmed.ncbi.nlm.nih.gov/32862143
Autor:
Michihiko Iijima, Daiji Kambe, Jun-ichi Karasawa, Yoshinori Sekiguchi, Shigeyuki Chaki, Takeshi Aoki, Shuji Yamamoto, Ayaka Kaku, Taketoshi Okubo, Shigeru Okuyama, Kumi Abe, Yasunori Kawakita, Toshiharu Shimazaki, Tsuyoshi Shibata
Publikováno v:
Psychopharmacology. 232:2849-2861
Since the hypofunction of the N-methyl-D-aspartate (NMDA) receptor is known to be involved in the pathophysiology of schizophrenia, the enhancement of NMDA receptor function through glycine modulatory sites is expected to be a useful approach for the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd1550386c90206545a89d0c456a020e
https://doi.org/10.1007/s00213-015-3920-3
https://doi.org/10.1007/s00213-015-3920-3
Autor:
Hiroyuki Koike, Daiji Kambe, Jun-ichi Karasawa, Hirohiko Hikichi, Kohnosuke Kinoshita, Ayaka Kaku, Shigeyuki Chaki, Kazuaki Kawaura
Publikováno v:
Behavioural Brain Research. 278:186-192
Glutamatergic dysfunction, particularly the hypofunction of N-methyl-D-aspartate (NMDA) receptors, is involved in the pathophysiology of schizophrenia. The positive modulation of the glycine site on the NMDA receptor has been proposed as a novel ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f151be3c0d0495da9517aa12771517
https://doi.org/10.1016/j.bbr.2014.09.046
https://doi.org/10.1016/j.bbr.2014.09.046
Publikováno v:
Journal of Pharmacological Sciences, Vol 122, Iss 1, Pp 10-16 (2013)
Glutamatergic dysfunction has been implicated in psychiatric disorders such as schizophrenia. Both the stimulation of the metabotropic glutamate (mGlu) 2/3 receptor and the blockade of the mGlu1 receptor have been shown to be effective in a number of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bed0678b5425e90b93c63c7cc71f7a2e
http://www.sciencedirect.com/science/article/pii/S1347861319303391
http://www.sciencedirect.com/science/article/pii/S1347861319303391
Publikováno v:
Psychopharmacology. 209:263-270
Glutamatergic abnormalities are involved in the etiology of schizophrenia. Clinical evidence demonstrates that positive modulation of "glycine modulatory sites" on N-methyl-D: -aspartic acid (NMDA) receptors improve cognitive deficits as well as posi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73aeb33f442ec69b2d85bd335d49c4e2
https://doi.org/10.1007/s00213-010-1794-y
https://doi.org/10.1007/s00213-010-1794-y
Autor:
Izumi Iida, Yasumitsu Tomishima, Hiroki Urabe, Ayaka Kaku, Toshiyuki Marumo, Akito Yasuhara, Hirohiko Hikichi, Jun-ichi Karasawa, Tomoko Tamita, Shigeyuki Chaki, Tetsuaki Hiyoshi
Publikováno v:
Journal of Pharmacological Sciences, Vol 127, Iss 3, Pp 352-361 (2015)
Glutamatergic dysfunction has been implicated in psychiatric disorders such as schizophrenia. The stimulation of metabotropic glutamate (mGlu) 2 receptor has been shown to be effective in a number of animal models of schizophrenia. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be2658fe1040fdd06d6fcdcee854dd1
https://pubmed.ncbi.nlm.nih.gov/25837934
https://pubmed.ncbi.nlm.nih.gov/25837934